This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Institut Pasteur. Active years: 2020-2023.
Company Filing History:
Years Active: 2020-2023
Title: Xavier Carnec: Innovator in Immunogenic Research
Introduction
Xavier Carnec is a notable inventor based in Lyon, France. He has made significant contributions to the field of immunogenic research, particularly through his work with recombinant attenuated Mopeia virus (MOPV). With a total of 2 patents, his innovations are paving the way for advancements in immune response therapies.
Latest Patents
Xavier Carnec's latest patents include an immunogenic composition comprising a recombinant attenuated Mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity. This patent describes a recombinant attenuated MOPV that encodes a nucleoprotein with attenuated exonuclease activity and optionally encodes a non-MOPV arenavirus glycoprotein. The use of this recombinant attenuated MOPV aims to induce an immune response in a subject. Another patent focuses on a similar recombinant attenuated Mopeia virus, emphasizing the modified nucleoprotein with reduced exonuclease activity and its application in immune response induction.
Career Highlights
Xavier Carnec is affiliated with the prestigious Institut Pasteur, where he conducts his research. His work is characterized by a commitment to developing innovative solutions in the field of immunology. His contributions have been instrumental in advancing the understanding of viral mechanisms and their potential therapeutic applications.
Collaborations
Xavier collaborates with esteemed colleagues such as Sylvain Baize and Stephanie Reynard. Their combined expertise enhances the research environment and fosters innovative approaches to immunogenic challenges.
Conclusion
Xavier Carnec's work exemplifies the intersection of innovation and scientific research. His patents and collaborations contribute significantly to the field of immunology, showcasing the potential of recombinant viruses in therapeutic applications.